The prospect of targeting inflammation to treat residual cardiovascular risk using the monoclonal antibody canakinumab (Ilaris) appears to be slim to none in the wake of recent decisions from ...
On 21 October 2019, the European Medicines Agency (EMA) published a guide for assessors of centralised applications for marketing authorisation. The guide focuses on the wording used in therapeutic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results